DOI 10.1016/j.bcmd.2026.103003
Delay in cell infusion improves GVHD and clinical outcomes in severe aplastic anemia patients >30 years receiving unrelated donor hematopoietic stem cell transplantation.
Аннотация
Circadian rhythms regulate immune cell activity, but their impact on hematopoietic stem cell infusion remains unclear. This retrospective study evaluated 177 severe aplastic anemia (SAA) patients undergoing unrelated donor hematopoietic stem cell transplantation (URD-HSCT) (2012-2023) to assess impacts of circadian infusion timing. No significant differences emerged between early and late infusion groups in cumulative incidence (CUI) of neutrophil/platelet engraftment, acute/chronic graft-versus-host disease (aGVHD/cGVHD), or CMV/EBV viremia. Notably, CUI of grade III-IV aGVHD was higher in the early group (5.7%, 95% CI: 1.8%-13.4%) versus 0% in the late group (95% CI: 0%-3.4%, P = 0.03). Five-year overall survival (OS: 87% vs. 93%, P = 0.1871), failure-free survival (FFS: 85% vs. 92%, P = 0.1389), and graft-versus-host disease/relapse-free survival (GRFS: 76% vs. 82%, P = 0.2781) showed no statistical disparities. Subgroup analysis revealed older patients (>30 years) receiving late peripheral blood HSCT had superior OS (78% vs. 97%, P = 0.0154) and FFS (78% vs. 94%, P = 0.0390). These data suggest that the timing of infusion may affect the risk of GVHD and the survival of older patients, for whom delayed infusion may confer a survival benefit.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.